Unknown

Dataset Information

0

Cytokine release syndrome in a patient with colorectal cancer after vaccination with BNT162b2.


ABSTRACT: Patients with cancer are currently prioritized in coronavirus disease 2019 (COVID-19) vaccination programs globally, which includes administration of mRNA vaccines. Cytokine release syndrome (CRS) has not been reported with mRNA vaccines and is an extremely rare immune-related adverse event of immune checkpoint inhibitors. We present a case of CRS that occurred 5 d after vaccination with BTN162b2 (tozinameran)-the Pfizer-BioNTech mRNA COVID-19 vaccine-in a patient with colorectal cancer on long-standing anti-PD-1 monotherapy. The CRS was evidenced by raised inflammatory markers, thrombocytopenia, elevated cytokine levels (IFN-γ/IL-2R/IL-18/IL-16/IL-10) and steroid responsiveness. The close temporal association of vaccination and diagnosis of CRS in this case suggests that CRS was a vaccine-related adverse event; with anti-PD1 blockade as a potential contributor. Overall, further prospective pharmacovigillence data are needed in patients with cancer, but the benefit-risk profile remains strongly in favor of COVID-19 vaccination in this population.

SUBMITTER: Au L 

PROVIDER: S-EPMC8363501 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC8127450 | biostudies-literature
| S-EPMC3364040 | biostudies-literature
| S-EPMC6825470 | biostudies-literature
| S-EPMC10248525 | biostudies-literature
| S-EPMC8712099 | biostudies-literature
| S-EPMC9188919 | biostudies-literature
2018-05-28 | GSE111236 | GEO
| S-EPMC6154787 | biostudies-literature
2021-09-09 | GSE168098 | GEO
| S-EPMC10234245 | biostudies-literature